Uroplasty Receives New Patent for Implantable Neuromodulation System and Method
MINNEAPOLIS, July 1 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,729,772 which covers a method for using an implantable neuromodulation system in the treatment of urinary incontinence by neuromodulation or stimulation of the tibial nerve. The neuromodulation system includes a portable, external transmitter and a receiver implanted subcutaneously in the leg or ankle near the tibial nerve.
"We are very pleased to have this new patent added to our overall intellectual property portfolio," said David Kaysen, President and CEO. "This newly-issued patent broadens our portfolio of neuromodulation patents, which includes patents covering our Urgent® PC System, a product we have commercialized in the U.S. since 2006 for the treatment of urinary urgency, urinary frequency, and urinary urge incontinence. While we have not begun work on nor have any current plans for product development related to this implantable neuromodulation patent, this newly-issued patent could offer an opportunity to broaden our product offering."
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent® PC System, which we believe is the only FDA-approved minimally invasive neuromodulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique®, an injectable bulking agent for the minimally invasive treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at www.uroplasty.com.
Forward-Looking Information
This press release contains forward-looking statements. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.
For Further Information: |
||
Uroplasty, Inc. |
EVC Group |
|
David Kaysen, President and CEO, or |
Doug Sherk (Investors) |
|
Medi Jiwani, Vice President, CFO, and Treasurer, |
415.896.6820 |
|
952.426.6140 |
Chris Gale (Media) |
|
646.201.5431 |
||
SOURCE Uroplasty, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article